Antiretroviral resistance testing in HIV infected patients improves health and saves costs

During HIV treatment resistance mutations of the virus to antiretroviral drugs may occur and the treatment regimen become less effective. In the present study the authors compared the cost-effectiveness of genotypic antiretroviral resistance testing versus expert opinion for treatment optimization in HIV infected patients with treatment failure.

The study is based on data from the Swiss HIV Cohort Study (www.shcs.ch), which is one of the largest cohort studies on HIV disease including patients from all University Clinics and two state hospitals in Switzerland. In this study, both health care costs and productivity costs, i.e. costs due to absence from work because of ill-health, were included in the analysis. Using most recent scientific methods, the authors could show that antiretroviral resistance testing not only increases life expectancy and quality-of-life, but also results in cost savings to society.

"This is the first study that shows that resistance testing not only improves the health of the patients but is also beneficial to the society at large when job productivity changes are considered," said Pedram Sendi, first author and principal investigator, from the Clinic of Infectious Diseases & Hospital Epidemiology of the Basel University Hospital. "We are convinced that our study will be noticed in many countries as it also documents the clinical benefit of antiretroviral resistance testing," comment Manuel Battegay from the Basel University Hospital and Huldrych Günthard from the Zurich University Hospital, co-principals of this cost-effectiveness study.

In times of increasing pressures to contain health care costs cost-effectiveness analyses are an important source of information to evaluate whether health interventions represent "value for money." This may help to prioritize resource allocation in health care by finding those health technologies that offer the most health outcomes for the resources invested. To date the Swiss HIV Cohort Study has conducted several cost-effectiveness analyses and has contributed to a better understanding of important cost-effectiveness issues in HIV disease.

Citation: Sendi P, Günthard HF, Simcock M, Ledergerber B, Schüpbach J, et al (2007) Cost-Effectiveness of Genotypic Antiretroviral Resistance Testing in HIV-Infected Patients with Treatment Failure. PLoS ONE 2(1): e173. doi:10.1371/journal.pone.0000173 (http://dx.doi.org/10.1371/journal.pone.0000173)

Source: Public Library of Science

Related stories:

Scientists identify genetic link that may neutralize HIV
Scientists from the Gladstone Institute of Virology and Immunology (GIVI) and the National Institutes of Allergy and Infectious Diseases (NIAID) have identified a gene that may influence the production of antibodies that neutralize HIV. This new information will likely spur a new approach for making an HIV vaccine that elicits neutralizing antibodies. Neutralizing antibodies, once produced in the host, can attack and checkmate an infecting virus. The research was reported in the September 5 issue of Science.
Adherence to antiretroviral therapy high in children in low income countries
Researchers from the Indiana University School of Medicine, the Regenstrief Institute and Moi University School of Medicine are the first to report that adherence to antiretroviral therapy (ART) to fight human immunodeficiency virus (HIV) in children who live in low income countries is as high as or higher than adherence by children living in high income countries.
New study finds HIV drug can persist in mothers' milk, increasing risk to them and their babies
A drug commonly used in the developing world to prevent transmission of HIV from mother to child persists in the breast milk and blood of the mothers, putting them and their babies at risk for developing drug-resistant strains of the virus, according to researchers at the Stanford University School of Medicine.
Strategies to control TB outdated, inadequate
The standard regimens to treat tuberculosis (TB) are inadequate in countries with high rates of multi-drug resistant (MDR) TB. In countries with high rates of MDR-TB, patients are nearly twice as likely to fail their initial treatment than those in countries with low rates, according to a new analysis of World Health Organization (WHO) data. This finding suggests strongly that current TB treatment regimens need to updated and revised to address the shifting landscape of public health in the face of MDR-TB.
How 'hidden mutations' contribute to HIV drug resistance
One of the major reasons that treatment for HIV/AIDS often doesn't work as well as it should is resistance to the drugs involved. Now, scientists at McGill University have revealed how mutations hidden in previously ignored parts of the HIV genome play an important role in the development of drug resistance in AIDS patients. Their study will be published Aug. 8 in the Journal of Biological Chemistry.
Genetic cause of innate resistance to HIV/AIDS
Some people may be naturally resistant to infection with HIV, the virus that causes AIDS. The results of a study conducted by Dr. Nicole Bernard of the Research Institute of the McGill University Health Centre (MUHC) bring us closer to a genetic explanation. Her study findings were published on July 16 in the journal AIDS.
Researchers identify potential new drug candidates to combat 'bird flu'
As the specter of a worldwide outbreak of avian or "bird flu" lingers, health officials recognize that new drugs are desperately needed since some strains of the virus already have developed resistance to the current roster of anti-flu remedies.
Psychosocial issues affect HIV/AIDS treatment outcomes
Psychosocial influences such as stress, depression and trauma have been neglected in biomedical and treatment studies involving people infected with HIV, yet they are now known to have significant health impacts on such individuals and the spread of AIDS, according to a University of North Carolina at Chapel Hill scientist.

News discussion:

Medicine & Health news